Journal Publications
Project Data Sphere's success is ultimately measured by the practice-changing scientific insights discovered by the research community. We are proud to share the following list of peer-accepted publications, and we are grateful to the data providers, research scientists, and patients that make this possible.
Author(s) |
Date | Article Title | Journal |
|---|---|---|---|
|
Anne A. Eaton, Emily C. Zabor |
December 2021 | Analysis of composite endpoints with component-wise censoring in the presence of differential visit schedules | Statistics in Medicine |
|
Anway Giryes, Hani Oweira, Meinrad Mannhart, and Omar Abdel-Rahman |
July 2018 | Impact of primary tumor side on the outcomes of patients with non-metastatic colon cancer; a patient-level pooled analysis of two clinical trials | Expert Review of Gastroenterology and Hepatology |
|
Aurélie Lombard, Hitesh Mistry, Leon Aarons, Kayode Ogungbenro |
October 2020 | Dose individualisation in oncology using chemotherapy‐induced neutropenia: Example of docetaxel in non‐small cell lung cancer patients | British Journal of Clinical Pharmacology |
|
Austin L. Johnson, Michael Anderson, Max Bouvette, Israel Pinero, Shelby Rauh, Bradley Johnson, Micah Kee, Benjamin Heigle, Andrea C. Tricco, Matthew J. Page, Patti McCall Wright, Matt Vassar |
November 2022 | Clinical Trial Data-sharing Policies Among Journals, Funding Agencies, Foundations, and Other Professional Organizations: A Scoping Review | Journal of Clinical Epidemiology |
|
Celine Yeh, Mengxi Zhou, Keith Sigel, Gayle Jameson, Ruth White, Rachael Safyan, Yvonne Saenger, Elizabeth Hecht, John Chabot, Stephen Schreibman, Béata Juzyna, Marc Ychou, Thierry Conroy, Tito Fojo, Gulam A Manji, Daniel Von Hoff, Susan E Bates |
November 2022 | Tumor Growth Rate Informs Treatment Efficacy in Metastatic Pancreatic Adenocarcinoma: Application of a Growth and Regression Model to Pivotal Trial and Real-World Data | The Oncologist |
|
CEO Roundtable on Cancer |
November 2020 | Merck KGaA, Darmstadt, Germany, Recognized for Collaborative Cancer Research by CEO Roundtable on Cancer | PR Newswire |
|
Charles Hugh-Jones, Robin Jenkins, Joel Beetsch, Kald Abdallah, Michael Curnyn, Fang Liz Zhou, Mace L. Rothenberg, Gregory A. Curt, John Dornan, Martin J. Murphy |
January 2017 | Overcoming barriers to develop a broad access data sharing platform | Journal of Clinical Oncology |
|
Charles Hugh-Jones, Robin Jenkins, Joel Beetsch, Kald Abdallah, Michael Curnyn, Fang Liz Zhou, Mace L. Rothenberg, Gregory A. Curt, John Dornan, Martin J. Murphy |
January 2017 | Overcoming barriers to develop a broad access data sharing platform | Journal of Clinical Oncology |
|
Chongyang Duan,Ao Yuan &Ming T. Tan |
May 2022 | Robust estimates of regional treatment effects in multiregional randomized clinical trials with ordinal responses | Journal of Biopharmaceutical Statistics |
|
Chun Pan, Bo Cai, Lianming Wang |
May 2020 | A Bayesian approach for analyzing partly interval-censored data under the proportional hazards model | Statistical Methods in Medical Research |
|
Daniel Caldeira, Beatriz Nogueira-Garcia, Ana Abreu & Fausto J. Pinto |
December 2022 | Fish intake and risk of cardiovascular events: an analysis of the VITAL cohort | European Journal of Clinical Nutrition |
|
Daniele Modonutti MD,Sami E. Majdalany MD,Nicholas Corsi BS,Pin Li PhD,Akshay Sood MD,Deepansh Dalela MD,Marcus L. Jamil MD,Clara Hwang MD,Mani Menon MD,Craig G. Rogers MD,Quoc-Dien Trinh MD,Giacomo Novara MD,Firas Abdollah MD |
July 2022 | A novel prognostic model predicting overall survival in patients with metastatic castration-resistant prostate cancer receiving standard chemotherapy: A multi-trial cohort analysis | The Prostate |
|
Deborah Plana, Geoffrey Fell, Brian M. Alexander, Adam C. Palmer & Peter K. Sorger |
February 2022 | Cancer patient survival can be parametrized to improve trial precision and reveal time-dependent therapeutic effects | Nature Communications |
|
Detian Deng, Yu Du, Zhicheng Ji, Karthik Rao, Zhenke Wu, Yuxin Zhu, R. Yates Coley |
November 2017 | Predicting survival time for metastatic castration resistant prostate cancer: An iterative imputation approach | F1000 Research |
